Supply status · FDA data
Is semaglutide or tirzepatide in shortage?
FDA's shortage decisions changed its policies for compounding pharmacies. We read FDA's drug shortage data every six hours and show the status of both products here, with FDA's key decisions and their sources.
GLP-1 shortage status
Semaglutide
No current shortage listing
FDA lists no semaglutide product as currently in shortage.
Last FDA shortage decision: February 21, 2025.
Other FDA listings
- Rybelsus, Tablet, 14 mg (NDC 0169-4314-30)To be discontinued · FDA update June 4, 2026
- Rybelsus, Tablet, 3 mg (NDC 0169-4303-30)To be discontinued · FDA update June 4, 2026
- Rybelsus, Tablet, 7 mg (NDC 0169-4307-30)To be discontinued · FDA update June 4, 2026
Tirzepatide
No current shortage listing
FDA lists no tirzepatide product as currently in shortage.
Last FDA shortage decision: December 19, 2024.
FDA's data last updated October 13, 2026 · Checked October 14, 2026 at 7:08 PM UTC · FDA Drug Shortages database · openFDA drug shortages API
FDA's key decisions
FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list for outsourcing facilities; comments were open until June 29, 2026. FDA source
FDA determined that the semaglutide injection shortage is resolved. FDA source
After reevaluating its decision, FDA again determined that the tirzepatide injection shortage is resolved. FDA source
FDA determined that the tirzepatide injection shortage is resolved. FDA source
What it means for your clinic
Supply and policy can change quickly. Clinics that keep a vetted primary pathway and a qualified backup on file can respond to a change without scrambling.
Compounded semaglutide and tirzepatide are prepared by licensed pharmacies on a valid prescription and are not FDA approved.
This page reports FDA's published data and decisions. It is not legal or medical advice; confirm the current status in FDA's database before acting on it.